5T1T

Irak4 kinase - compound 1 co-structure


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.34 Å
  • R-Value Free: 0.228 
  • R-Value Work: 0.206 
  • R-Value Observed: 0.207 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.

Smith, G.F.Altman, M.D.Andresen, B.Baker, J.Brubaker, J.D.Chen, H.Chen, Y.Childers, M.Donofrio, A.Ferguson, H.Fischer, C.Fischmann, T.O.Gibeau, C.Hicks, A.Jin, S.Kattar, S.Kleinschek, M.A.Leccese, E.Lesburg, C.Li, C.Lim, J.Liu, D.Maclean, J.K.F.Mansoor, F.Moy, L.Y.Mulrooney, E.F.Necheva, A.S.Presland, J.Rakhilina, L.Yang, R.Torres, L.Zhang-Hoover, J.Northrup, A.

(2017) Bioorg Med Chem Lett 27: 2721-2726

  • DOI: 10.1016/j.bmcl.2017.04.050
  • Primary Citation of Related Structures:  
    5T1S, 5T1T

  • PubMed Abstract: 
  • Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. Medicinal chemistry optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity ...

    Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. Medicinal chemistry optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity. These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation.


    Organizational Affiliation

    Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Interleukin-1 receptor-associated kinase 4A, B, C, D301Homo sapiensMutation(s): 0 
Gene Names: IRAK4
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NWZ3 (Homo sapiens)
Explore Q9NWZ3 
Go to UniProtKB:  Q9NWZ3
PHAROS:  Q9NWZ3
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
76P (Subject of Investigation/LOI)
Query on 76P

Download Ideal Coordinates CCD File 
E [auth A], F [auth B], G [auth C], H [auth D]~{N},~{N}-dimethyl-4-(6-nitroquinazolin-4-yl)oxy-cyclohexan-1-amine
C16 H20 N4 O3
UCYLWJABRYZSHN-AULYBMBSSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
SEP
Query on SEP
A, B, C, DL-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A, B, C, DL-PEPTIDE LINKINGC4 H10 N O6 PTHR
Binding Affinity Annotations 
IDSourceBinding Affinity
76P Binding MOAD:  5T1T IC50: 58 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.34 Å
  • R-Value Free: 0.228 
  • R-Value Work: 0.206 
  • R-Value Observed: 0.207 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 143α = 90
b = 139.56β = 124.45
c = 87.34γ = 90
Software Package:
Software NamePurpose
AutoPROCdata scaling
XDSdata reduction
SCALAdata scaling
BUSTERrefinement

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

  • Deposited Date: 2016-08-22 
  • Released Date: 2017-05-03 
  • Deposition Author(s): Fischmann, T.O.

Revision History  (Full details and data files)

  • Version 1.0: 2017-05-03
    Type: Initial release
  • Version 1.1: 2017-06-28
    Changes: Database references
  • Version 1.2: 2017-11-22
    Changes: Refinement description